{"id":"W2736373206","doi":"10.1200/jco.2017.35.15_suppl.10525","title":"Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1<sup>+</sup> advanced, relapsed, or refractory solid tumor or lymphoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Refractory (planetary science); Internal medicine; Metastatic melanoma; Lymphoma; Phases of clinical research; Oncology; Melanoma; Cancer; Progressive disease; Disease; Surgery; Nuclear medicine; Clinical trial; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146482,0.001158461,0.0007459135,0.0002253285,0.0002659702,0.0004591562,0.0006035839,0.0008018024,0.005487419],"category_scores_gemma":[0.0004652541,0.0004182519,0.0004584682,0.0002263931,0.0004356432,0.0005697148,0.0003014432,0.00205187,0.0009533569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009235607,"about_ca_system_score_gemma":0.001348843,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007763511,"about_ca_topic_score_gemma":0.002622208,"domain_scores_codex":[0.9997737,0.0001114089,0.00001092546,0.00003584011,0.00002605435,0.00004203725],"domain_scores_gemma":[0.9997419,0.00003480131,0.0000759758,0.00001462827,0.0000188837,0.0001140152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5184377,0.08992635,0.04021763,0.002694962,0.001332989,0.001402593,0.0006730656,0.004857293,0.111554,0.001651397,0.03940783,0.1878443],"study_design_scores_gemma":[0.476283,0.4352439,0.04392352,0.0001492239,0.0006898249,0.001995988,0.0001427489,0.00257628,0.01231392,0.0003778869,0.02626238,0.00004125723],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794226,0.003229307,0.001116214,0.0008329451,0.0001265247,0.005707826,0.004815632,0.0001484333,0.004600438],"genre_scores_gemma":[0.9689716,0.003317971,0.004974628,0.001772277,0.0002050667,0.005207021,0.008887942,0.0000531672,0.006610459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005487419,"threshold_uncertainty_score":0.01835722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0674205008324529,"score_gpt":0.4443536176567062,"score_spread":0.3769331168242533,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}